Inherited movement disorders

Neurologic Clinics

Volumn 20, Issue 3, 2002, Pages 759-778

  Sharma, Nutan ^a   Standaert, David G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACANTHOCYTOSIS; CHOREOATHETOSIS; CLINICAL FEATURE; DYSTONIA; GENETIC ANALYSIS; GENETIC DISORDER; HALLERVORDEN SPATZ DISEASE; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PEDIGREE; PRIORITY JOURNAL; REVIEW; WILSON DISEASE;

EID: 0036699606     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(01)00014-7     Document Type: Article

References (111)

1. Kokmen E, Ozekmekci FS. Beard, Cm, O'Brien, PC, Kurland, LT. Incidence and prevalence of Huntington's disease in Olmsted county, Minnesota (1950 through 1989). Arch Neurol 1994;51:696-8.
2. Harper P. The natural history of Huntington's disease. In: Harper P, editor. Huntington's disease, London: WB Saunders; 1996. P. 123-36.
3. Bruyn G, Wendt LN. Extrapyramidal disorders. In: Handbook of clinical neurology, Vinken P, Bruyn GW, Klawans HL, editors. Amsterdam, Netherlands: Elsevier Science; 1986. P. 267-314.
4. Folstein S. Huntington's disease: a disorder of families. Baltimore: Johns Hopkins University Press; 1989.
5. Hayden M. Huntington's Chorea. New York: Springer-Verlag; 1981.
6. Lasker AG, Hain TC, Folstein SE, Singer HS. Saccades in Huntington's disease: initiation defects and distractility. Neurology 1987;37:364-70.
7. Penney Jr. JB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-9.
8. Young AB, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986;36:244-9.
9. Rasmussen A MR, Yescas P, Ochoa A, Davila G, Alonso E. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics 2000;4:190-4.
10. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
11. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-81.
12. Goldberg YP, Andrew SE, Theilmann J, Graham RK, Squitieri F, Telenius H, et al. Molecular analysis of new mutations for Huntington's disease, intermediate alleles and sex of origin effects. Nat Genet 1993;5:174-9.
13. Myers RH, Koroshetz WJ, Duyao MP, Ambrose CM, Taylor SA, Barnes G, et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet 1993;5:168-173.
14. Rubinsztein DC, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996;59:16-22.
15. Durr A, Hahn-Barma V, Brice A, Pecheux C, Dode C, Feingold J. Homozygosity in Huntington's disease. J Med Genet 1999;36:172-3.
16. Duyao M AC, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993;4:387-92.
17. Brinkman R, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington's disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-10.
18. MacDonald ME, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet 1993;30:982-6.
19. Harper P, Shaw D. Huntington's disease: genetic and molecular studies. In: Harper P, editor. Huntington's disease. London: WB Saunders; 1996. P. 241-92.
20. Harper P, Soldan J, Tyler A. Predictive tests in Huntington's disease. In: Harper P, editor. Huntington's disease. London: WB Saunders; 1996. P. 395-424.
21. Vonsattel JP, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77.
22. Hedreen J, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133:257-61.
23. Roos R. Neuropathology of Huntington's chorea. In: Vinken P, Bruyn G, Klawans H, editors. Handbook of clinical neurology: extrapyramidal disorders. Amsterdam, Netherlands: Elsevier; 1986. P. 315-26.
24. Sotrel A, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991;41:1117-23.
25. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
26. Tanner C, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-33.
27. Mark M. Lumping and splitting the Parkinson plus syndromes. Neurol Clin 2001;19:607-28.
28. Berciano J. Olivopontocerebellar atrophy: a review of 117 cases. J Neurol Sci 1982;53:253-72.
29. Houlden H, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-6.
30. Kawaguchi Y, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221-8.
31. Tanner C, Ottman R, Goldman S, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
32. DeStefano A, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, et al. Genome-wide scan for Parkinson's disease: the GenePD study. Neurology 2001;57:1124-6.
33. Polymeropoulos M, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
34. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30 Pro mutation in the gene encoding alpha synuclein in Parkinson's disease, Nat Genet 1998;18:106-8.
35. Vaughan J, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y, et al. Sequencing of the alpha synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. Hum Mol Genet 1998;7:751-3.
36. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature 2001;2:492-501.
37. Matsumine H, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25:2-27. Am J Hum Genet 1997;60:588-96.
38. Lucking C, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the Parkin gene. N Engl J Med 2000;342:1560-7.
39. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5.
40. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-9.
41. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
42. Beal M. Experimental models of Parkinson's disease. Nature Reviews 2001;2:325-332.
43. Feany M, Bender WW. A drosophila model of Parkinson's disease. Nature 2000;404:394-8.
44. Standaert D, Young AB. Parkinson's disease. In: Pharmacological basis of therapeutics. Hardman J, Limbird LE, editors. New York: McGraw-Hill; 2001.
45. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1971-3.
46. Cox D, Roberts E. Wilson's disease. In: Gene clinics: medical genetics knowledge base. Seattle: University of Washington Press; 1999.
47. Gow Sr. PJ, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000;46:415-19.
48. Patten B. Wilson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Philadelphia: Williams and Wilkins; 1993.
49. Dening T, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989;38:1126-34.
50. Roberts E, Cox DW. Wilson's disease. Ballieres clin Gastroenterol 1998;12:237-56.
51. Steindl P, Dienes HP, Grimm G, Pabinger I, Madl C, Maier-Dobersberger T, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997;113:212-18.
52. Walshe J. Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. Q J Med 1989;70:253-63.
53. Scheinberg I. Investigating diseases no one's got. N Engl J Med 1983;309:918-19.
54. Bull PC, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-37.
55. Mercer J. The molecular basis of copper-transport diseases. Trends in Mol Med 2001;7:64-9.
56. Friedman J, Standaert DG. Dystonia and its disorders. Neurol Clin 2001;19:681-705.
57. Brewer G, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin KJ. Treatment of Wilson's disease with zinc XVII: treatment during pregnancy. Hepatology 2000;31:364-70.
58. LeWitt P. Penicillamine as a controversial treatment for Wilson's disease. Mov Disord 1999;14:555-6.
59. Dooling E, Schoene WC, Richardson EP. Hallervorden-Spatz syndrome. Arch Neurol 1974;30:70-83.
60. Swaiman K. Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol 1991;48:1285-93.
61. Newell F, Johnson RO 2nd, Huttenlocher PR. Pigmentary degeneration of the retina in Hallervorden-Spatz syndrome. Am J Ophthalmol 1979;88:467-71.
62. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227-34.
63. Sethi KD AR, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988;24:692-4.
64. Zhou B, Westaway Sk, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PNKK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-9.
65. Fahn S. Paroxysmal dyskinesias. In: Marsden C, Fahn S, editors. Movement disorders. Oxford: Butterworth-Heineman; 1994.
66. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995;38:571-9.
67. Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 1967;17:680-90.
68. Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Semin Neurol 1999;19:271-95.
69. Tomita H, Nagamitsu S, Wakui K, Fukushima Y, Yamada K, Sadamatsu M, et al. Paroxysmal kinesigenic choreoathetosis locus maps to chromosome 16p 11.2-q12.1 Am J Hum Genet 1999;65:1688-97.
70. Wein T, Andermann F, Silver K, Dubeau F, Andermann E, Rourke-Frew F, et al. Exquisite sensitivity of paroxysmal kinesigenic choreoathetosis to carbamazepine. Neurology 1996;47:1104-6.
71. Hardie RJ, Harding AE, Owen JS, Pires M, Daniels GL, Imai Y, et al. Neuroacanthocytosis. a clinical haematological and pathological study of 19 cases. Brain 1991;14:13-49.
72. Rampoldi L, Dobson-Stone C, Rubio JP, Danek A, Chalmers RM, Wood NW, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001;28:119-20.
73. Ueno S, Maruki Y, Nakamura M, Tomemori Y, Kamae K, Tanabe H, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001;28:121-2.
74. Jankovic J, Fahn S. Dystonic Disorders. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins; 1998. P. 513-52.
75. Bressman S, de Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, et al. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol 1994;36:771-7.
76. Bressman S, de Leon D, Raymond D, Ozelius LJ, Breakefield XO, Nygaard TG, et al. Clinical-genetic spectrum of primary dystonia. In: Fahn S, Marsden CD, DeLong M, editors. Dystonia 3: advances in neurology. Philadelphia: Lippincott-Raven; 1998. P. 79-91.
77. Kramer P, Heiman GA, Gasser T, Ozelius LJ, de Leon D, Brin MF, et al. The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Hum Genet 1994;55:468-75.
78. Ozelius L, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17:40-8.
79. Ozelius L, Kramer PJ, de Leon D, Risch N, Bressman SB, Schuback DE, et al. Strong allelic association between the torsin dystonia gene (DYT1) and loci on chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 1992;50:619-28.
80. Warner T, Fletcher NA, Davis MB, Ahmad F, Conway D, Feve A, et al. Linkage analysis in British and French families with idiopathic torsion dystonia. Brain 1993;116:739-44.
81. Augood S, Martin DM, Ozelius LJ, Breakefield XO, Penney JB, Standaert DG. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann Neurol 1999;46:761-9.
82. Bressman S, Sabatti C, Raymond D, de Leon D, Klein C, Kramer PL, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000;54:1746-52.
83. Bressman SB, Heiman GA, Brin MF, Burke RE, Fahn S, Trugman JM, et al. Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystonia. Mov Disord 1994;9:626-32.
84. Valente E, Warner TT, Jarman PR, Mathen D, Fletcher NA, Marsden, et al. The role of DYT1 in primary torsion dystonia in Europe. Brain 1998;121:2335-9.
85. Lee L, Pascasio FM, Fuentes FD, Viterbo GH. Torsion dystonia in Panay, Philippines. Adv Neurol 1976;14:137-51.
86. Muller U, Steinberger D, Nemeth AH. Clinical and molecular genetics of primary dystonia. Neurogenetics 1998;1:165-77.
87. Kupke K, Lee LV, Muller U. Assignment of the X-linked torsion dystonia gene to Xq21 by linkage analysis. Neurology 1990;40:1438-42.
88. Waters C, Faust PL, Powers J, Vinters H, Moskowitz C, Nygaard TG, et al. Neuropathology of Lubag (X-linked dystonia-parkinsonism). Mov Disord 1993;8:387-90.
89. Waters C, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ, Nygaard TG, et al. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women. Neurology 1993;43:1555-8.
90. Graeber M, Kupke KG, Muller U. Delineation of the dystonia-parkinsonism syndrome locus in Xq13. Proceedings of the National Academy of Science 1992;89:8245-8.
91. Haberhausen G, Schmitt I, Kohler A, Peters U, Rider S, Chelly J, et al. Assignment of the dystonia-parkinsonism syndrome locus, DYT3, to a small region within a 1.8 -Mb YAC contig of Xq13.1. Am J Hum Genet 1995;57:644-50.
92. Wilhelmsen K, Weeks DE, Nygaard TG, Moskowitz CB, Rosales RL, dela Paz DC, et al. Genetic mapping of lubag (x-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991;29:124-131.
93. Eidelberg DTS, Wilhelmsen K, Dhawan V, Chaly T, Robeson W, Dahl R, et al. Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism. Ann Neurol 1993;34:185-91.
94. Gasser T. Inherited myoconus-dystonia syndrome. Adv Neurol 1998;78:325-34.
95. Quinn N. Essential myoclonus and myoclonis dystonia. Mov Disord 1996;11:119-24.
96. Quinn N, Rothwell JC, Thompson PD, Marsden CD. Heditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol 1988;50:391-401.
97. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, et al. Mutations in the gene encoding E-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001;29:66-9.
98. Imamura M, Araishi K, Noguchi S, Ozawa E. A sarcoglycan-dystroglycan complex anchors Dp116 and utrophin in the peripheral nervous system. Hum Mol Genet 2000;9:3091-100.
99. McNally E, Ly CT, Kunkel LM. Human epsilon-sarcoglycan is highly related to alphasarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEBS Lett 1998;422:27-32.
100. Nygaard T. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol 1993;60:577-85.
101. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation. In: Hereditary progressive dystonia with marked diurnal fluctuation. Segawa M, Editor. New York: Parthenon Publishing; 1993.
102. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976;14:215-33.
103. Furukawa Y, Trugman JM, Bird TD, Hunter A, Sadeh M, Tagawa T, et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 1998;50:1015-20.
104. Steinberger D WY, Korinthenberg R, Deuschl G, Benecke R, Martinius J, Muller U. High penetrance and pronounced variation in expressivity of GCH1 mutations in five families with dopa-responsive dystonia. Ann Neurol 1998;43:634-9.
105. Nygaard T, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991;41:174-81.
106. Bandmann O DS, Marsden CD, Wood NW, Harding AE. The GTP-cyclohydrolase I gene in aytpical parkinsonian patients: a clinico-genetic study. J Neurol Sci 1996;141:27-32.
107. Bandmann O, Marsden CD, Wood NW. Atypical presentations of dopa-responsive dystonia. Adv Neurol 1998;78:283-90.
108. Furukawa Y, Kish SJ. Dopa-responsive dystoia: Recent advances and remaining issues to be addressed. Mov Disord 1999;14:709-15.
109. Ichinose H, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994;8:207-9.
110. Jeon BS, Park SS, Lee MC. Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. Adv Neurol 1998;78:309-17.
111. Knappskog P, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995;4:1209-12.